Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.

Ren C, Zhang G, Han F, Fu S, Cao Y, Zhang F, Zhang Q, Meslamani J, Xu Y, Ji D, Cao L, Zhou Q, Cheung KL, Sharma R, Babault N, Yi Z, Zhang W, Walsh MJ, Zeng L, Zhou MM.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7949-7954. doi: 10.1073/pnas.1720000115. Epub 2018 Jul 16.

PMID:
30012592
2.

BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.

Cheung K, Lu G, Sharma R, Vincek A, Zhang R, Plotnikov AN, Zhang F, Zhang Q, Ju Y, Hu Y, Zhao L, Han X, Meslamani J, Xu F, Jaganathan A, Shen T, Zhu H, Rusinova E, Zeng L, Zhou J, Yang J, Peng L, Ohlmeyer M, Walsh MJ, Zhang DY, Xiong H, Zhou MM.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):2952-2957. doi: 10.1073/pnas.1615601114. Epub 2017 Mar 6.

3.

Structural features and inhibitors of bromodomains.

Meslamani J, Smith SG, Sanchez R, Zhou MM.

Drug Discov Today Technol. 2016 Mar;19:3-15. doi: 10.1016/j.ddtec.2016.09.001. Epub 2016 Sep 22. Review.

4.

Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.

Yang X, Li F, Konze KD, Meslamani J, Ma A, Brown PJ, Zhou MM, Arrowsmith CH, Kaniskan HÜ, Vedadi M, Jin J.

J Med Chem. 2016 Aug 25;59(16):7617-33. doi: 10.1021/acs.jmedchem.6b00855. Epub 2016 Aug 11.

5.

The bromodomain: from epigenome reader to druggable target.

Sanchez R, Meslamani J, Zhou MM.

Biochim Biophys Acta. 2014 Aug;1839(8):676-85. doi: 10.1016/j.bbagrm.2014.03.011. Epub 2014 Mar 28. Review.

6.

ChEpiMod: a knowledgebase for chemical modulators of epigenome reader domains.

Meslamani J, Smith SG, Sanchez R, Zhou MM.

Bioinformatics. 2014 May 15;30(10):1481-3. doi: 10.1093/bioinformatics/btu052. Epub 2014 Jan 27.

7.

Computational profiling of bioactive compounds using a target-dependent composite workflow.

Meslamani J, Bhajun R, Martz F, Rognan D.

J Chem Inf Model. 2013 Sep 23;53(9):2322-33. doi: 10.1021/ci400303n. Epub 2013 Aug 26.

PMID:
23941602
8.

Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling.

Meslamani J, Li J, Sutter J, Stevens A, Bertrand HO, Rognan D.

J Chem Inf Model. 2012 Apr 23;52(4):943-55. doi: 10.1021/ci300083r. Epub 2012 Apr 11.

PMID:
22480372
9.

Enhancing the accuracy of chemogenomic models with a three-dimensional binding site kernel.

Meslamani J, Rognan D.

J Chem Inf Model. 2011 Jul 25;51(7):1593-603. doi: 10.1021/ci200166t. Epub 2011 Jun 21.

PMID:
21644501
10.

sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins.

Meslamani J, Rognan D, Kellenberger E.

Bioinformatics. 2011 May 1;27(9):1324-6. doi: 10.1093/bioinformatics/btr120. Epub 2011 Mar 12.

PMID:
21398668
11.

Assessing the geometric diversity of cytochrome P450 ligand conformers by hierarchical clustering with a stop criterion.

Meslamani JE, André F, Petitjean M.

J Chem Inf Model. 2009 Feb;49(2):330-7. doi: 10.1021/ci800275k.

Supplemental Content

Loading ...
Support Center